Similar findings have been reported in studies involving partial agonists of the tropomyosin receptor kinase B (TrkB) and C (TrkC), where synaptic deficits were rescued in the APP model of AD despite enhanced expression of microglial neuroinflammatory markers and immune responses typically associated with late-stage pathology [112]. Here, NTRK2 is linked to Alzheimer disease.